Globus Medical Acquires Nevro Corp to Innovate Chronic Pain Management Solutions
- Globus Medical is acquiring Nevro Corp. for $250 million to enhance its chronic pain management portfolio.
- The acquisition aims to integrate Nevro’s innovative technologies, including the HFX iQ™ spinal cord stimulation system.
- Closing of the acquisition is anticipated in Q2 2025, pending shareholder and regulatory approvals.
Globus Medical’s Strategic Acquisition: A Step Towards Innovation in Pain Management
Globus Medical, a leader in the musculoskeletal implant and device industry, is poised to enhance its portfolio significantly through its strategic acquisition of Nevro Corp., a company specializing in chronic pain treatment solutions. Nevro recently reported its fourth-quarter and full-year financial results for 2024, revealing a decrease in revenue, which reflects the current challenges in the medical device market. The planned acquisition, valued at approximately $250 million, underscores Globus Medical's commitment to expanding its offerings and improving patient outcomes in the chronic pain management space. This move is particularly relevant as the demand for effective pain management solutions continues to grow, driven by an aging population and increasing prevalence of chronic conditions.
In the fourth quarter, Nevro experienced a 9.1% drop in worldwide revenue, with U.S. revenues also declining by 9.9%. The company reported a decrease in both permanent implant and trial procedures, which signals challenges in its operational performance. However, CEO Kevin Thornal remains optimistic, emphasizing that Nevro's adjusted EBITDA exceeded expectations due to strong financial management. By integrating Nevro’s innovative technologies, such as the HFX iQ™ spinal cord stimulation system, Globus Medical can leverage these advancements to offer a broader range of effective solutions for chronic pain, an area that has seen increasing demand and competition.
The acquisition is set to close in the second quarter of 2025, pending necessary shareholder and regulatory approvals. This timeline aligns with the anticipated market introduction of Nevro's HFX iQ™ system, which recently received CE Mark certification for the European market. The system's advanced features, including HFX AdaptivAI™, promise to enhance pain management strategies significantly. Additionally, recent studies highlight the effectiveness of Nevro's high-frequency spinal cord stimulation therapy in treating diabetic neuropathy, further solidifying the strategic rationale behind Globus Medical's acquisition. By incorporating these innovations, Globus Medical can address a critical need in the healthcare market, positioning itself as a frontrunner in chronic pain management solutions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

